Product and Sanofi Details

TELFAST® SUSPENSION Fexofenadine hydrochloride 6 mg/ml. Reg. No. 42/5.7.1/0339

TELFAST® 120 Tablets Fexofenadine hydrochloride 120 mg/tab. Reg. No. 32/5.7.1/0446

TELFAST® 180 Tablets Fexofenadine hydrochloride 180 mg/tab. Reg. No. 32/5.7.1/0447

For full prescribing information refer to the professional information approved by the Regulatory Authority.
Applicant: sanofi-aventis south africa (pty) ltd, Reg. no.:
1996/010381/07. Sanofi House, 2 Bond Street, Grand Central Ext. 1, Midrand, 1685. Tel: (011) 256 3700
www.sanofi.com

Contact Us

Side Effects / Safety:
za.Drugsafety@sanofi.com

Medical Queries:
za.CHCenquiries@sanofi.com

Product Quality Complaints:
za.productqualitycomplaints@sanofi.com

MARKETING AUTHORISATION HOLDER

MARKETING AUTHORISATION HOLDER

Side Effects / Safety:
za.Drugsafety@sanofi.com

Medical Queries:
za.CHCenquiries@sanofi.com
Product Quality Complaints:
za.productqualitycomplaints@sanofi.com

FULL PRESCRIBING INFORMATION

FULL PRESCRIBING INFORMATION

FULL PRESCRIBING INFORMATION ARE AVAILABLE UPON REQUEST AT:

Sanofi Regional Office, Jumeirah Lakes Towers, Dubai, UAE.
To report adverse events, please call: +971561747001
Or email: gulf.pharmacovigilance@sanofi.com.

Personal health questions must be discussed with healthcare professionals.
You should consult a physician or pharmacist before using a medicinal product. With best wishes from Ministry of Health and Prevention.